Canada Cancer Pain Management Market Report 2022 to 2030

Canada Cancer Pain Management Market Analysis

$ 3999

Canada's Cancer Pain Management market is projected to grow from $521.6 Mn in 2022 to $788.43 Mn by 2030, registering a CAGR of 5.3 % during the forecast period of 2022 - 2030. The main factors driving the growth would be an increase in cancer cases, advancements in pain management technologies and treatment, and government support and initiatives. The market is segmented by drug type and by disease. Some of the major players include WEX Pharmaceuticals (CAN), Tetra Bio-Pharma (CAN), Pfizer, Teva Pharmaceuticals, and Medtronic.

ID: IN10CAHS002 CATEGORY: Healthcare Services GEOGRAPHY: Canada AUTHOR: Neha Davda

Buy Now

Canada Cancer Pain Management Market Executive Summary

Canada's Cancer Pain Management market is projected to grow from $521.6 Mn in 2022 to $788.43 Mn by 2030, registering a CAGR of 5.3 % during the forecast period of 2022 - 2030. In 2019, Canada's national healthcare expenditure was seen to rise high up to 10.84% of its GDP from 10.81% in 2018. The cost of medical treatment is highest for seniors. Despite the fact that per-person spending increased significantly with age, from $6,656 for those aged 65 to 69 to $20,793 for those aged 80 and older, population aging is only a modest driver of rising healthcare expenditures, contributing only approximately 1% annually. The overall trend for health spending as a share of Canada's GDP is upward.

Cancer pain may result from the actual condition of cancer or from related procedures like surgery and chemotherapy. Medication selection and use are influenced by the kind, location, and intensity of pain experienced. Different medications are used to treat cancer pain. For instance, it is preferable to utilize strong opioids in cases of severe pain rather than non-opioids like acetaminophen and NSAIDs when treating mild to moderate cancer pain. North America holds a significant portion of the global market for cancer pain management.

canada cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The Canada cancer pain management market is expected to be driven by factors such as an increase in cancer cases, advancements in pain management technologies and treatment, and government support and initiatives. The government is heavily funding cancer research and treatment because it is the top cause of disease-related death in children and adolescents in Canada. The Canadian Institutes of Health Research (CIHR) recently announced $23 million in funding to create the Canadian Pediatric Cancer Consortium (CPCC), which will also expand the nation's market for cancer pain management.

Market Restraints

Some pain management drugs have side effects such as nausea, dizziness, urinary retention, sleep issues, and constipation, which can limit their use and have an impact on the growth of the cancer pain relief market. Further, the availability of these drugs for some cancer patients may be restricted due to severe limits that Canadian regulators have put in place around the prescription of prescription opioids in an attempt to control the opioid epidemic.

Competitive Landscape

Key Players

WEX Pharmaceuticals (CAN)
Tetra Bio-Pharma (CAN)
Pfizer
Teva Pharmaceuticals
Medtronic

Notable Recent Deals

July 2020: Tetra and Mondias jointly announce the acquisition of Lumiera Health Innovation. The purchase of Lumiera Health Innovation has been announced jointly by Tetra and Mondias. With this acquisition, Tetra is able to concentrate on what it does best: creating innovative, medically effective cannabinoid-based treatments for ophthalmic conditions, chronic pain (both cancer-related and not-related to cancer), and advanced cancer pain.

Healthcare Policies and Regulatory Landscape

The Canada Health Act, which specifies the national standards for healthcare services, governs the country's healthcare system. The provinces and territories control pain management, which is classified as a medical service. The Ministry of Health in each province regulates pain management in Canada. Additionally, Health Canada, which is in charge of approving and overseeing the use of pain management drugs, regulates the pharmaceutical industry. The goals of the pain management policy are to guarantee that patients receive safe and efficient care while simultaneously addressing problems like opioid addiction and prescription drug theft.

Reimbursement Scenario

The federal and provincially funded public healthcare system in Canada serves as the primary driver of the reimbursement scenario for the pain management market. The public healthcare system covers the bulk of pain management treatments, including medications and surgical procedures. Some private insurance policies, however, might provide additional coverage for specific therapies. Each province decides how much it will reimburse for pain management procedures, and the amount can change depending on the kind of procedure, the patient's health, and the number of funds that is available.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.